A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

AI also supports reverse vaccinology, where pathogen genomes are computationally analyzed to identify immunogenic regions ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

Now, mRNA vaccines can be quickly created against different antigenic targets by changing the mRNA sequence, and companies are looking beyond COVID-19 at other infectious diseases, including ...

The researchers added that with routine vaccination declining and also impacted by cuts to the US' foreign aid, the study ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...